92 results
Page 4 of 5
6-K
EX-99.1
kjf9q3efsvpdf54ivbnw
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am
424B5
al7oncpin5ybtdr
23 Sep 20
Prospectus supplement for primary offering
8:06am
6-K
EX-99.1
61ufiy7x8yn
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
424B5
srmaojtspfwelv qfw
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
iag zai058ci2e
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
EX-99.1
z511 61obfym527a1gj
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
zumgyvpfn2yeqnd
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
EX-99.1
rse 5l8mwn6b
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
424B2
w734pkkr
24 Jan 20
Prospectus for primary offering
7:24am
424B5
ocrun2g wloz
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
zhn7l
14 Jan 20
Zai Lab Appoints Lonnie Moulder to Board of Directors
7:30am
20-F/A
EX-10.15
yz7zms9ob5cj4c 0rc
23 Aug 19
Annual report (foreign) (amended)
5:00pm
6-K
EX-99.1
a0p72bexhfyh4g jkr
2 Jul 19
Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
7:32am
20-F/A
EX-10.15
iczv ir8j1x
26 Jun 19
Annual report (foreign) (amended)
6:07am
424B2
nkx0vng
6 May 19
Prospectus for primary offering
6:04am
424B5
gzmde9ycuphicm
1 May 19
Prospectus supplement for primary offering
5:26pm